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Abstract
Background Colon transit (CT) measurements are
used in the management of significant constipation.
The radiopaque marker (ROM) method provides
limited information. Methods We proposed to validate
wireless motility capsule (WMC), that measures pH,
pressure and temperature, to ROM measurement of CT
in patients with symptomatic constipation evaluated
at multiple centers. Of 208 patients recruited, 158 eli-
gible patients underwent simultaneous measurement
of colonic transit time (CTT) using ROM (Metcalf
method, cut off for delay >67 h), and WMC (cutoff for
delay >59 h). The study was designed to demonstrate
substantial equivalence, defined as diagnostic agree-
ment >65% for patients who had normal or delayed
ROM transit. Key Results Fifty-nine of 157 patients
had delayed ROM CT. Transit results by the two
methods differed: ROM median 55.0 h [IQR 31.0–85.0]
and WMC (43.5 h [21.7–70.3], P < 0.001. The positive
percent agreement between WMC and ROM for
delayed transit was80%; positive agreement in 47 by
WMC/59 by ROM or 0.796 (95% CI = 0.67–0.98);
agreement vs null hypothesis (65%) P = 0.01. The
negative percent agreement (normal transit) was
91%: 89 by WMC/98 by ROM or 0.908 (95%
CI = 0.83–0.96); agreement vs null hypothesis (65%),
P = 0.00001. Overall device agreement was 87%. There
were significant correlations (P < 0.001) between ROM
and WMC transit (CTT [r = 0.707] and between ROM
and combined small and large bowel transit
[r = 0.704]). There were no significant adverse events.
Conclusions & Inferences The 87% overall agreement
(positive and negative) validates WMC relative to
ROM in differentiating slow vs normal CT in a
multicenter clinical study of constipation.
Keywords colonic transit time, correlation, negative
agreement, positive agreement, radiopaque markers,
wireless motility capsule.
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INTRODUCTION
Chronic constipation is a common disorder and affects
approximately 20% of the US population.1 Systematic
evaluation of the disorder includes detailed history,
clinical evaluation and, in patients who do not respond
to dietary changes and laxatives, objective assessment
of colonic and anorectal function.2,3
In clinical practice, chronic functional constipation
is defined by symptoms rather than specific abnormal-
ities in physiology. Patients with chronic functional
constipation may have a wide variety of symptoms
including reduced stool frequency, hard stool consis-
tency, straining, a sense of incomplete evacuation,
and/or the need to use manual maneuvers to defecate.
This diversity in clinical presentation is reflected in
symptom-based diagnostic criteria.4,5
Because symptoms are poor predictors of underlying
pathophysiology, physiological assessment of gastro-
intestinal (GI) tract transit is often indicated. In
combination with measures of anorectal and pelvic
floor function, transit assessments have been shown
to facilitate a diagnosis of slow transit constipation
and evacuation disorder although overlap exists
among the conditions.3 In order to assess regional
transit times, gastric emptying can be evaluated with
scintigraphy using a technetium labeled egg sandwich
meal and colonic transit time (CTT) with radio
opaque markers.6–8 Whole gut transit can be evaluated
using scintigraphy,9–11 but this technique is expen-
sive, involves radiation, and has limited clinical
availability.
The wireless motility capsule (WMC) simulta-
neously measures the GI and colonic pH, temperature,
and intraluminal pressure. The capsule can be used to
measure whole gut transit and also regional GI transit,
through identification of characteristic changes in pH
profile down the GI tract, i.e., abrupt rise in pH on
exiting the stomach, and rapid drop in pH from
alkaline to mildly acid on passage through the ileocecal
region. By utilizing this latter pH change as an
indication of the onset of colonic transit, and also the
temperature change associated with expulsion through
defecation, Rao et al. 12 recently demonstrated the
ability of the WMC to estimate colonic transit. The
latter study also suggested that WMC may be able to
assess colonic transit in patients with constipation.
The study hypothesis is that WMC provides a
comparable evaluation of colonic and combined small
intestinal and colonic transit to radiopaque markers
(ROM) to identify slow transit in patients with consti-
pation, as defined by Rome III criteria. The study was
designed to compare simultaneously CTT as measured
by ROM and WMC in a multicenter study in patients
with symptomatic chronic constipation. The primary
objective of this trial was to demonstrate the statistical




This multicenter validation study (Protocol number 120508) was
designed to validate the WMC by measuring transit in patients
with symptomatic chronic constipation and comparing to the
widely used, quantitative segmental ROM protocol8 in which 24
markers are ingested each day for three successive days with
abdominal radiographs on the fourth and seventh day to count the
number of ROM remaining in the abdomen. While performing the
comparison of simultaneously measured colonic transit, the study
served to establish the distribution of transit measurements in
patients with chronic constipation relative to the normal data and
threshold values (cut offs) previously established in healthy
participants.12
Participants
The study was designed to enroll 150 subjects with chronic
functional constipation using criteria adapted from Rome III
criteria with amendment to emphasize abnormal stool consis-
tency. Eligibility criteria included: both genders between ages of
18–80 years with symptoms of chronic functional constipation for
at least one year; self-reported hard stool at least 25% of the time
with at least one of the six symptoms of functional constipation
as defined by ome III criteria (such as self-reported bowel
movement frequency of <3 bowel movements/week for at least
3 of the last 6 months [4]). Participating study centers, prohibited
medications and comparator method 8 are included in the
Appendix.
Conduct of the study
Subjects participated in the study for approximately 2 weeks
during which they attended the following study visits:
Visit 1 – Screening – for approximately 1 h.
Visit 2 – WMC and ROM ingestion – for approximately 1 h.
Patients then took the ROM on day 2 and 3 on their own.
Visit 3 – Abdominal radiograph on day 4 – for approximately
1 h.
Visit 4 – Second abdominal radiograph, if necessary, on day 7 –
for approximately 1 h. The radiograph was not indicated if all the
ROM and WMC had been expelled on the day 4 radiograph.
Throughout the study participants maintained a daily diary to
record stool consistency by Bristol stool form scale;13 participants
were encouraged to maintain the usual daily fiber intake and to
follow their usual exercise routine.
WMC Method
The method for measuring gastric emptying, small bowel and
colonic transit using the WMC has been described in detail in
prior publications.12,14,15 The WMC incorporates sensors for pH,
temperature, and pressure and transmits sensed data at 434 MHz.
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The single use capsule measures from 0.5 to 9.0 pH units with an
accuracy of ±0.5 pH units; pressure from 0 to 350 mmHg with an
accuracy of ±5 mmHg up to 100 mmHg, and accuracy of ±10%
above 100 mmHg, and temperature from 25 to 49 C with an
accuracy of ±1 C. The data are transmitted electronically and are
recorded by a portable receiver worn by the participant. The
receiver has rechargeable batteries with a life of around 6–7 days.
Thus, pH, motility, and temperature data are collected over time
and exit from the body is signaled when the ambient, environ-
mental temperature is sensed rather than body temperature. All
data are initially downloaded from the receiver through a docking
station via a USB connection to a Windows PC-compatible laptop
computer, as previously described.15 The SMARTPILL GI Monitoring
System Version 1.3.1 (SmartPill Corp., Buffalo, NY, USA) was
used in this study. Prior studies had established the cut off for
delayed CTT was 59 h;12 for combined small and large bowel
transit time (SLBTT), the cutoff was 65 h (95th percentile for
healthy participants, data on file, SmartPill Corporation).
The primary WMC parameter for comparison to ROM is CTT.
A secondary endpoint for this method is the combined SLBTT.
This is used as the surrogate measure of colonic transit when CTT
is not available. The literature demonstrates that emptying of a
solid large particle from the stomach including this WMC usually
required gastric migrating motor complex (MMC) activity 14
because of the sieving function of the pylorus;16 on the other
hand, the small bowel transit time of such a large particle does not
absolutely require MMCs17 and, in general, large particles are able
to traverse the ileocecal region with bolus movements that
traverse this region.18 SLBTT also closely approximates CTT
because the SBTT is generally 3–6 h, whereas colonic transit is
generally 24–60 h in asymptomatic people.
The WMC estimates of CTT and SLBTT were calculated by a
team overseen by one author (JS) all blinded to the ROM transit
results. Data were centralized and statistical analysis completed
by the statistician (GW) and first author (MC).
Adverse events
Adverse events were collected using system organ class and
preferred terms, and tabulated. All adverse events were recorded.
PI for each study site determined classification severity. An
independent medical safety monitor resolved any disputed
adverse events.
Statistical considerations
The primary objective of this trial was to demonstrate the
equivalence between the diagnostic test under evaluation (WMC)
and ROM colonic transit using the quantitative segmental
Metcalf method 8 for distinguishing delayed and normal transit
in patients with chronic constipation. Device agreement was
assessed relative to the comparator method, ROM, which provides
an indication of delayed or normal transit.
The primary endpoints of this trial were positive and negative
percent agreements between WMC CTT and ROM colonic transit
and between WMC SLBTT and ROM colonic transit. A positive
and negative percent agreement of more than 0.65 was considered
the minimum clinically acceptable level of agreement.
In the analysis, the WMC CTT cutoff [59 h12] and the ROM
quantitative segmental CTT cutoff used clinically [67 h8] were
applied to symptomatic patients who fulfilled eligibility criteria,
and did not have device malfunction or were disqualified for non-
compliance. Exact binomial tests were performed to evaluate both
positive and negative percent agreement, each at the 0.0253
significance level in order to achieve an overall significance level
of 0.05.19 This design required a total of 150 patients in order to
achieve approximately 0.83 power to detect differences of 10
percentage points (0.65 vs 0.75).
We used Wilcoxon-signed rank test to compare results obtained
by ROM for colonic transit, and for CTT and SLBTT by WMC. We
explored further analyses including correlations between ROM
and WMC measurements of CTT and SLBTT, and between CTT
by WMC and stool frequency and stool consistency using the
Bristol stool form scale.13
We also described, as secondary objectives, the gastric empty-
ing and small bowel transit times for the overall group and for the
patients classified as STC or NTC by ROM or by WMC CTT.
RESULTS
Participants, dispositions, and technical
considerations
Consort style flow chart demonstrates disposition of

























Figure 1 Consort flow chart of participants
in study: 208 patients enrolled in the study
with 158 successfully completing the study
with analyzable data. The five subjects who
were not compliant failed to attend the stu-
dy site for the required abdominal radiograph
for radiopaque marker (ROM) transit mea-
surement.
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data were used for comparison of WMC with ROM
comparator method, 20 were male (13%) and 138 female
(87%); age was 42.5 ± 12.2 years. The racial distribution
was as follows: Caucasian 83%, Black 13%, Asian/
Pacific Islanders 2%, Hispanic 1%, and other 1%.
One hundred and eighty subjects participated in the
study, ingesting WMC and ROM. Nine participants
were excluded because of the intake of prohibited
concomitant medications including prohibited antibi-
otics, laxatives, opiate medication, and a proton pump
inhibitor. Thirteen other participants were excluded
because of either device malfunction or non-compli-
ance (Fig. 1).
Data from the 158 subjects were used for the
assessment of device agreement between the ROM
and WMC’s CTT and WMC’s SLBTT. In one subject,
the value for CTT was missing due to the absence of
the typical ileocecal junction pH change and conse-
quent inability to identify the start of colonic transit.
In four other subjects, SLBTT could not be estimated
due to absence of the typical change in pH that is used
to identify the time of exit of the capsule from the
stomach. Thus, assessment of colonic transit was
based on comparisons between CTT by WMC and
ROM in 157 patients, and comparison between SLBTT
by WMC and ROM in 154 patients.
Comparison of WMC and ROM for CTT
Table 1 shows the positive percent agreement between
the WMC CTT cutoff of 59 h and ROM’s quantitative
segmental CTT cutoff of 67 h. Forty-seven of the 59
patients with delayed colonic transit by ROM were
also shown to have delayed CTT by WMC. The
positive percent agreement of WMC CTT and ROM
was 80% (47/59 = 0.796, 95% CI = 0.67–0.98), which
is statistically significant vs the null hypothesis of
65% agreement, (P = 0.01). Similarly, the negative
percent agreement is 91% (89/98 = 0.908, 95%
CI = 0.83–0.96), which is statistically significant vs
the null hypothesis of 65% agreement (P = 0.00001).
Overall device agreement is 87% (that is [47 + 89]/
[59 + 98], and 95% CI 0.80–0.92).
Comparison of WMC and ROM for small bowel
and CTT
Table 2 shows the positive percent agreement between
the WMC combined SLBTT cutoff of 65 h and ROM’s
quantitative segmental CTT cutoff of 67 h. Forty-six of
the 58 subjects delayed by ROM were delayed by WMC
SLBTT. The positive percent agreement for WMC
SLBTT and ROM is 80% (46/58 or 0.793, 95% CI
0.67–0.89), which is statistically significant vs the null
hypothesis of 65% agreement (P = 0.01). Similarly, the
negative percent agreement is 91% (87/96 = 0.906,
95% CI, 0.83–0.96), which is statistically significant
vs the null hypothesis of 65% agreement (P = 0.00001).
Overall device agreement is 86%.
Gastric and small bowel transit times
Table 2 summarizes gastric emptying time and small
bowel transit time for the overall group and for the
patients classified as STC or NTC by ROM or by WMC
CTT. The prevalence of WMC gastric emptying time
>5 h (cut-off used to suggest gastroparesis [15]) was 28/
152 (18.3%) in these patients with constipation; 13
patients had slow colonic transit, and 15 had normal
colonic transit.
Relationship between WMC and ROM marker
estimates of colonic transit
Fig. 2 shows a summary of the estimated CTT and
SLBTT by WMC and CTT by ROM. While there is
clear overlap between groups, the paired analysis
shows significant differences in the actual WMC
estimates for CTT (43.5 h [21.7–70.3], P < 0.001) and
SLBTT (median 47.0 h, [IQR 25.8–75.1] P = 0.013,
Wilcoxon-signed rank test) relative to the ROM esti-
mated CTT (median 55.0 h [IQR 31.0–85.0]).
Fig. 3 shows a significant correlation between WMC
measurements and ROM markers for both CTT
(r = 0.707, P < 0.001) and SLBTT (r = 0.704, P < 0.001).
Relationship between wireless capsule estimates
of transit and bowel function
Spearman coefficients were used to explore the corre-
lation between CTT and SLBTT by WMC and stool
Table 1 Number of patients with agreement (a) between CTT by
WMC and Day 4 + Day 7 ROM colonic transit (+, delayed; ), normal
transit) and (b) between small and large bowel TT by WMC and day
4 + day 7 ROM colonic transit (+, delayed; ), normal transit)
D4 + D7 ROM+ D4 + D7 ROM) Total
(a)
WMC CTT+ 47 9 56
WMC CTT) 12 89 101
Total 59 98 157
(b)
WMC SLBTT+ 46 9 55
WMC SLBTT) 12 87 99
Total 58 96 154
CTT, colonic transit time; WMC, wireless motility capsule; ROM,
radiopaque marker.
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consistency using Bristol stool form scale and stool
frequency. Data were complete from 154 of the 158
patients and show a significant, but only moderate,
correlation of CTT and SLBTT with stool consistency
(respectively, r = )0.399 and r = )0.427, both
P < 0.0001). In contrast, the correlations with stool
number per day (frequency) were non-significant
(respectively, r = )0.015, P = 0.85, and r = )0.023,
P = 0.78).
Adverse events
No issues of safety were raised during the study and no
serious adverse events were reported. In Table 3, all
adverse events reported during the trial are listed by
category. There were two females (38 and 50 years old)
who were unable to swallow the capsule, and one
female (47 years old) who experienced abdominal
cramping (starting 90 min after swallowing the cap-
sule). These adverse events were classified as definitely
related to WMC. Both subjects experiencing dysphagia
ingested WMC after repeated attempts and completed
the test without further incident. Symptoms in the
patient with abdominal cramping abated after 4 h. The
subject reported no additional symptoms during the
entire test and she completed the study without
further incident. Abdominal radiographs at 4 and
7 days showed no features to suggest mechanical
obstruction and confirmed that the capsule had exited
the body by day 7. One case each of abdominal
cramping, nausea, and loose or soft stools were
recorded as possibly related to the device. There were
no serious adverse events and no incidents of capsule
retention requiring intervention with colonoscopy or
endoscopy.
DISCUSSION
This study has demonstrated that the colonic transit
measured by WMC significantly correlated with the
widely used comparator, ROM. Categorization of con-
stipated subjects into slow or normal colonic transit
based on WMC studies matched closely with ROM
studies. Specifically, WMC estimate of colonic transit
fulfills the expected concordance of at least 65% with
ROM, validating WMC to determine whether colonic
transit profile is normal or delayed.
There are numerical differences in the actual colonic
transit estimates by the WMC and ROM techniques.
This is not unexpected given the evidence that particle
Table 2 Median (25th, 75th percentile) gastric emptying and small bowel transit times in minutes, as determined by the WMC, in patients classified
by both ROM and WMC
Overall group
Gastric emptying time Small bowel transit time Orocecal transit time
185 (157, 248) 234 (201, 293) 437 (381, 531)
NTC STC NTC STC NTC STC
Classified by ROM 179 (148, 244) 196 (166, 259) 234 (199, 285) 233 (201, 315) 429 (380, 528) 479 (389, 622)
Classified by WMC 179 (152, 243) 197 (165, 292) 232 (194, 285) 236 (205, 322) 425 (374, 528) 505 (419, 618)













ROM (D4+7) WMC CTT WMC SLBTT
Figure 2 Colonic transit time (CTT) and small and large bowel
transit time (SLBTT) by wireless motility capsule (WMC) and colonic
transit time by radiopaque marker (ROM) in the entire patient
cohort with evaluable data. Data show median, interquartile range
(box), 5–95 percentile (whiskers) and outliers as individual points.
Note that, while there is clear overlap between the data by each
method of transit estimation, the paired analysis shows significant
differences in the WMC estimates for CTT (P < 0.001) and SLBTT
(P = 0.013, Wilcoxon-signed rank test) relative to the ROM estimated
colonic transit time. For reference purposes, note that 95th percen-
tiles in healthy controls are 67 h for ROM transit, 59 h for CTT, and
65 h for SLBTT.
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size influences the transit of solid particles in the small
bowel and colon. For example, Stivland et al.20
observed differences between transit of 1-mm diameter
pellets and 4 mm ROM. Van der Sijp et al.21 docu-
mented faster transit of ROM relative to smaller
radioisotopically labeled particles. Similarly, indigest-
ible capsules travel more quickly through the colon
than ROM, and capsule transit is faster than small
dispersed particles.22,23
Radiopaque marker assesses whole gut transit as it
assesses the location of the markers relative to the
time of marker ingestion rather than the time of onset
of colonic transit. Inclusion of gastric emptying and
small bowel transit time to the transit estimate could
140
160
WMC CTT = 10.653 + (0.670 * ROM (D4+7)),
R = -0.707, P < 0.001
140
160
WMC SLBTT = 14.884 + (0.672 * ROM (D4+7)),
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Figure 3 Relationship between colonic tra-
nsit time (CTT) and small and large bowel
transit time (SLBTT) by wireless motility
capsule (WMC) and colonic transit time by
radiopaque marker (ROM) (at day 4 plus 7) in
the entire patient cohort with evaluable
data. Note the significant correlations be-
tween WMC estimates and ROM transit
time. Interrupted line shows the 95% CI
around the regression line. The shaded areas
show the values at and above the 95th per-
centiles for the different methods: 67 h for
ROM transit, 59 h for CTT, and 65 h for
SLBTT. *Refers to multiplication.
Table 3 Adverse events











System organ class Preferred term
Gastrointestinal disorders Abdominal pain 0 1 1 0 1
Diarrhea 0 0 1 0 0
Dysphagia 0 0 0 0 2
Frequent bowel movements 0 2 0 0 0
Gastrointestinal pain 0 1 0 0 0
Nausea 1 2 2 0 0
Vomiting 1 2 0 0 0
General disorders and
administrative site conditions
Pyrexia 0 1 0 0 0
Sluggishness 1 0 0 0 0
Infections and infestations Bronchitis 1 0 0 0 0
Cystitis 1 0 0 0 0
Ear infection 1 0 0 0 0
Pharyngitis streptococcal 1 0 0 0 0
Tooth abscess 1 0 0 0 0
Upper respiratory tract infection 1 0 0 0 0
Injury, poisoning and procedural
complications
Postprocedural complication 1 0 0 0 0
Musculoskeletal and connective
tissue disorders
Muscle spasms 1 0 0 0 0
Nervous system disorders Headache 1 1 0 0 0
Migraine 1 0 0 0 0
Respiratory, thoracic and
mediastinal disorders
Asthma 1 0 0 0 0
Total number of adverse events 14 10 4 0 3
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account for 6–10 h difference between the colon transit
(CT) time by ROM and the WMC technique. The
absolute number estimate for CTT is therefore less
relevant than the correct classification of subjects
having a normal or delayed transit and the sensitivity
and specificity of the test.
The patients in this study represent the spectrum of
colonic transit profiles usually encountered in clinical
practice, with 40% having objectively delayed colo-
nic transit by the standard ROM method. This multi-
center cohort of patients with constipation reflects the
experience of documented slow transit in 38–80% of
patients with constipation in other studies3,24 adding
to the generalizability of the data in this study to
clinical practice.
The pH change as the capsule traverses from the
ileum to the colon determines the time of onset of CT
with WMC. The pH in the cecum is more acidic than
that of the ileum because of the fermentation of
digestive residue by colonic anerobic flora and the
nature and concentration of the colonic flora.25,26 This
pH drop at the ileocecal junction is well documented in
the medical literature 26–28 with the use of ingestible
radiotelemetry capsules initially in healthy volunteers
and subsequently in patients with a variety of diseases
including inflammatory bowel disease29 and adenomas
in the colon, and even in children.26 Overall, pH
profiles in the GI tract are characterized by an abrupt
rise in pH between the stomach and duodenum, a slow
continued rise in pH through the small bowel until
reaching the cecum where pH decreases about 1 unit,
and subsequently, there is a slow rise in pH through
the colon. In general, these changes in pH differed
slightly in health and disease, for example, pH decrease
was greater in the healthy subjects (7.4–5.8) than in the
Crohn’s disease patients [7.3–6.729], but the observed
decrease in both populations was sufficient to identify
transition from ileum to cecum. A recent scintigraphic
study has validated this pH change at the ileocolonic
junction and has shown that the fall in pH observed
with WMC corresponds to the time of arrival of the
WMC (labeled with a radioisotope) into the cecum or
ascending colon [the anatomy having been outlined
with use of a different radioisotope30]. In this valida-
tion study, we did not assess the effect of different
amounts or types of fiber intake, the effect of vigorous
exercise, or the potential influence of significant
sigmoid diverticulosis and hypertrophy of the muscu-
laris propria. These conditions might alter the pH
profile at the ileocecal region or the propulsion or
retention of the capsule through the distal colon.
Formal prospective studies will be required to address
these questions.
Occasionally, the pH drop at the ileocecal junction is
not clearly discernible, as occurred in one participant
in the current study. Reasons for the lack of the pH
drop are not understood but may be related to the
bacteria in the cecum, and previous food intake. In four
participants, we could not clearly identify the rise in
pH between the stomach and duodenum and this
compromised assessment of the SLBTT. Therefore,
there might be difficulty in interpreting the test in <1%
for CTT and 3–4% for SLBTT, consistent with previous
studies.12,15
The study also showed the relationship between
CTT and SLBTT measured by the WMC and stool
consistency measured by Bristol stool form scale,
rather than stool frequency, confirming a prior study.31
This is consistent with the significant relationship
between colonic transit by scintigraphy and stool form
in pharmacodynamic studies of renzapride or linaclo-
tide.32,33 In 10 healthy volunteers, there was significant
correlation between overall, gastric and colonic transit
measured by scintigraphy and by WMC.34
This study has therefore provided validation of the
WMC to estimate colonic transit, by showing good
agreement between the WMC and ROM method. The
agreement and correlation in this study are higher than
the study of Rao et al.12 that used a simplified ROM
method to assess colonic transit with a single abdom-
inal radiograph taken 5 days after marker ingestion. It
is relevant to note that relative to ROM, the WMC
provides a 20% misdiagnosis in slow transit constipa-
tion and a false positive rate of 9% in normal transit
constipation. However, this assumes that ROM is a
‘gold standard’; whereas, it should be termed a non-
reference standard. The WMC is able to characterize
pressure activity in the colon in health and disease
states.35 Studies are now under way to determine
whether additional information of clinical relevance is
provided by measurement of colonic contractile func-
tions. The ability to measure transit and pressures has
the potential to enhance the ability of gastroenterolo-
gists and surgeons in practice to assess patients with
suspected motility disorders such as gastroparesis and
slow transit constipation. This general availability of a
technique with standardized and automated analysis
contrasts with the lack of general applicability or
availability of whole gut scintigraphy and intubated
intraluminal manometry available at tertiary referral
centers.36–38 Capsule based methods do not expose
patients to radiation, in contrast to radioscintigraphy
and ROM methods, the latter requiring multiple
fluoroscopic or radiologic images.39
Other capsule techniques are reported to measure GI
motility non-invasively, without radiation exposure,
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using very different techniques and measuring differ-
ent dimensions of motor function. A magnet tracking
analyses the origin, direction, amplitude and velocity
of movements of a magnetic capsule relative to space–
time plots detected through a detection matrix (4 · 4
magnetic field sensors) and dedicated software im-
planted in a laptop computer.40 At present, this is a
research technique in non-ambulant subjects. Image
analysis with capsule endoscopy detects contractile
patterns (phasic luminal closure and radial wrinkles by
wall texture analysis), non-contractile patterns, intes-
tinal content, and endoluminal motion.41 It was used
in patients with small intestinal motility disorders and
in healthy volunteers exposed to glucagon.42
There are potential pitfalls with using all capsules to
measure gut transit including technical failures, inabil-
ity to swallow the capsule, the potential for non-
passage of or intestinal obstruction by the capsule in
stenosing gut disorders, and greater cost relative to the
ROM transit method. Application of the WMC is
contraindicated in patients with known esophageal or
intestinal strictures, and children under 18 years of
age, in whom validation studies have not yet been
completed.
In conclusion, the WMC provides a clinically rele-
vant estimate of colonic transit that is able to differ-
entiate slow from normal transit constipation.
Wireless motility capsule technology has the potential
to bring valid, non-invasive motility measurements to
the practice of gastroenterology in the community.
ACKNOWLEDGMENTS
The study was supported by a ‘New York State Foundation for
Science, Technology and Innovation Grant.’ Funding grant sup-
port was received by all study centers from the SmartPill
Corporation, Buffalo, New York. Dr. Camilleri was supported in
part by grant RO1-DK-54681 from National Institutes of Health.
The authors acknowledge the excellent contribution of gastroen-
terology colleagues at the different medical centers who helped
conduct this study: Ashok Attaluri, MD, University of Iowa;
Shanthini Daniel, MD, Jasper Clinic; Javier Gomez, MD, Temple
University; Otto Linet, MD, Jasper Clinic; Sahar D. Mohammed,
MD, Queen Mary University, London; Suwebatu Odunsi-Shiyan-
bade, MD, Mayo Clinic; Irene Sarosiek, MD, Texas Tech Univer-
sity. Clinical Trials.gov identifier: NCT00857363.
AUTHORS’ CONTRIBUTIONS
Dr. Camilleri: study conceptualization, study center PI, data
interpretation, writing protocol and paper; Dr. Rao: study concep-
tualization, study center PI, writing protocol and paper; Dr.
Parkman: study conceptualization, study center PI, writing pro-
tocol and paper; Dr. Kuo: study conceptualization, study center PI,
writing protocol and paper; Dr. Semler: study conceptualization,
writing protocol and paper; Dr. Wilding: study conceptualization,
statistical analyses, writing protocol and paper, Dr. Hasler: study
conceptualization, study design and implementation, and writing
paper, Dr. Gupta: study conceptualization, study center PI, and
writing paper, Dr. McCallum: study conceptualization, study
center PI, and writing paper, Dr. Thorne: study center PI, and
writing paper, Dr. Scott: study center PI, and writing paper, Dr.
Soffer: study center PI, and writing paper, Dr. Ringel: study center
PI, and writing paper, Dr. Esfandyari: study center PI, and writing
paper.
CONFLICT OF INTEREST
Dr. Camilleri serves as a consultant to SmartPill Corporation,
with compensation to Mayo Clinic, not to him. He received grant
support to participate in this study. Dr. Rao, Dr. Hasler, Dr. Kuo,
Dr. McCallum, Dr Parkman, Dr. Scott, Dr. Wilding serve as
speakers, consultants, or advisory board members for the Smart-
Pill Corporation. These authors and Dr. Soffer have received
research funding for other research studies from the SmartPill
Corporation. Dr. Semler is an employee of the SmartPill Corpo-
ration and owns stock in the SmartPill Corporation.
REFERENCES
1 Higgins DR, Johanson JF. Epidemiol-
ogy of constipation in North Amer-
ica: a systematic review. Am J
Gastroenterol 2004; 99: 750–9.
2 Lembo A, Camilleri M. Chronic
constipation. N Engl J Med 2003; 349:
1360–8.
3 Rao SS, Ozturk R, Laine L. Clinical
utility of diagnostic tests for constipa-
tion in adults: a systematic review. Am
J Gastroenterol 2005; 100: 1605–15.




5 Brandt LJ, Prather CM, Eamonn MM
et al. Systematic review on the man-
agement of chronic constipation in
North America. Am J Gastroenerol
2005; 100: S5–21.
6 Hinton JM, Lennard-Jones JE, Young
AC. A new method for studying gut
transit times using radioopaque
markers. Gut 1969; 10: 842–7.
7 Arhan P, Devroede G, Jehannin B
et al. Segmental colonic transit time.
Dis Colon Rectum 1981; 24: 625–9.
8 Metcalf AM, Phillips SF, Zinsmeister
AR, MacCarty RL, Beart RW, Wolff
BG. Simplified assessment of seg-
mental colonic transit. Gastroenter-
ology 1987; 92: 40–7.
9 Camilleri M, Colemont LJ, Phillips
SF et al. Human gastric emptying and
colonic filling of solids characterized
by a new method. Am J Physiol 1989;
257: G284–90.
10 Camilleri M, Zinsmeister AR.
Towards a relatively inexpensive,
noninvasive, accurate test for colonic
motility disorders. Gastroenterology
1992; 103: 36–42.
11 Bonapace ES, Maurer AH, Davidoff S,
Krevsky B, Fisher RS, Parkman HP.
Whole gut transit scintigraphy in the
clinical evaluation of patient with
upper and lower gastrointestinal
symptoms. Am J Gastroenterol 2000;
95: 2338–47.
12 Rao SS, Kuo B, McCallum RW et al.
Investigation of colonic and whole-
gut transit with wireless motility
capsule and radiopaque markers in
Volume 22, Number 8, August 2010 Wireless motility capsule vs ROM for colon transit
 2010 Blackwell Publishing Ltd 881
constipation. Clin Gastroenterol
Hepatol 2009; 7: 537–44.
13 Heaton KW, Radvan J, Cripps H,
Mountford RA, Braddon FE, Hughes
AO. Defecation frequency and tim-
ing, and stool form in the general
population: a prospective study. Gut
1992; 33: 818–24.
14 Cassilly D, Kantor S, Knight LC et al.
Gastric emptying of a non-digestible
solid: assessment with simultaneous
SmartPill pH and pressure capsule,
antroduodenal manometry, gastric
emptying scintigraphy. Neurogastro-
enterol Motil 2008; 20: 311–9.
15 Kuo B, McCallum RW, Koch KL et al.
Comparison of gastric emptying of a
nondigestible capsule to a radio-
labelled meal in healthy and gastro-
paretic subjects. Aliment Pharmacol
Ther 2008; 27: 186–96.
16 Meyer JH, Thomson JB, Cohen MB,
Shadchehr A, Mandiola SA. Sieving of
solid food by the canine stomach and
sieving after gastric surgery. Gastro-
enterology 1979; 76: 804–13.
17 Sarr MG, Kelly KA. Patterns of
movement of liquids and solids
through canine jejunum. Am J Phys-
iol 1980; 239: G497–503.
18 Phillips SF, Quigley EM, Kumar D,
Kamath PS. Motility of the ileoco-
lonic junction. Gut 1988; 29: 390–
406.
19 Pepe MS. The Statistical Evaluation
of Medical Tests for Classification
and Prediction. New York: Oxford
University Press, 2003.
20 Stivland T, Camilleri M, Vassallo M
et al. Scintigraphic measurement of
regional gut transit in idiopathic
constipation. Gastroenterology 1991;
101: 107–15.
21 van der Sijp JR, Kamm MA, Nightin-
gale JM et al. Radioisotope determi-
nation of regional colonic transit in
severe constipation: comparison with
radio opaque markers. Gut 1993; 34:
402–8.
22 Holdstock DJ, Misiewicz JJ, Smith T,
Rowlands EN. Propulsion (mass
movements) in the human colon and
its relationship to meals and somatic
activity. Gut 1970; 11: 91–9.
23 Hebden JM, Gilchrist PJ, Blackshaw E
et al. Night-time quiescence and
morning activation in the human
colon: effect on transit of dispersed
and large single unit formulations.
Eur J Gastroenterol Hepatol 1999; 11:
1379–85.
24 Ravi K, Bharucha AE, Camilleri M,
Rhoten D, Bakken T, Zinsmeister
AR. Phenotypic variation of colonic
motor functions in chronic constipa-
tion. Gastroenterology 2010; 138: 89–
97.
25 Fallingborg J, Christensen LA, Ing-
eman-Nielsen M et al. Measurement
of gastrointestinal pH and regional
transit times in normal children.
J Pediatr Gastroenterol Nutr 1990; 11:
211–4.
26 Fallingborg J, Christensen LA, Ing-
eman-Nielsen M et al. Gastrointesti-
nal pH and transit times in healthy
subjects with ileostomy. Aliment
Pharmacol Ther 1990; 4: 247–53.
27 Evans DF, Pye G, Bramley R, Clark
AG, Dyson TJ, Hardcastle JD. Mea-
surement of gastrointestinal pH pro-
files in normal ambulant human
subjects. Gut 1988; 29: 1035–41.
28 Watson BW, Meldrum SJ, Riddle HC,
Brown RL, Sladen GE. pH profile of
gut as measured by radiotelemetry
capsule. Br Med J 1972; 2: 104–6.
29 Fallingborg J, Pedersen P, Jacobsen
BA. Small intestinal transit time and
intraluminal pH in ileocecal resected
patients with Crohn’s disease. Dig
Dis Sci 1998; 43: 702–5.
30 Zarate N, Mohammed S, O’Shaugh-
nessy E et al. Accurate localisation of
a fall in pH within the ileo-caecal re-
gion. Neurogastroenterol Motil 2009
:21(Suppl. 1):43 (abstract)
31 Saad RJ, Chey WD, Rao SS et al.
Reduced stool frequency does not
predict colonic and whole gut transit
in constipated patients. Gastroen-
terology 2009;136 (Suppl. 1):M1209
(abstract)
32 Camilleri M, McKinzie S, Fox J et al.
Effect of renzapride on transit in
constipation-predominant irritable
bowel syndrome. Clin Gastroenterol
Hepatol 2004; 2: 895–904.
33 Andresen V, Camilleri M, Busciglio I
et al. Effect of 5 days linaclotide on
transit and bowel function in females
with constipation-predominant irri-
table bowel syndrome. Gastroenter-
ology 2007; 133: 761–8.
34 Maqbool S, Parkman HP, Friedenberg
FK. Wireless capsule motility: com-
parison of the SmartPill((R)) GI Mon-
itoring System with scintigraphy for
measuring whole gut transit. Dig Dis
Sci 2009; 54: 2167–74.
35 Hasler WL, Saad RJ, Rao SR et al.
Heightened coln motor activity mea-
sured by a wireless capsule in patients
with constipation: relation to colon
transit and IBS. Am J Physiol Gas-
trointest Liver Physiol 2009; 297:
G1107–14.
36 Charles F, Camilleri M, Phillips SF,
Thomforde GM, Forstrom LA. Scin-
tigraphy of the whole gut: clinical
evaluation of transit disorders. Mayo
Clin Proc 1995; 70: 113–8.
37 Bonapace ES, Maurer AH, Davidoff S,
Krevsky B, Fisher RS, Parkman HP.
Whole gut transit scintigraphy in the
clinical evaluation of patients with
upper and lower gastrointestinal
symptoms. Am J Gastroenterol 2000;
95: 2838–47.
38 Dinning PG, Bampton PA, Andre J
et al. Abnormal predefecatory colonic
motor patterns define constipation in
obstructed defecation. Gastroenterol-
ogy 2004; 127: 49–56.
39 Sadik R, Stotzer PO, Simrén M,
Abrahamsson H. Gastrointestinal
transit abnormalities are frequently
detected in patients with unexplained
GI symptoms at a tertiary centre.
Neurogastroenterol Motil 2008; 20:
197–205.
40 Hiroz P, Schlageter V, Givel JC,
Kucera P. Colonic movements in
healthy subjects as monitored by a
magnet tracking system. Neuro-
gastroenterol Motil 2009; 21: 838–57.
41 Malagelada C, De Iorio F, Azpiroz F
et al. New insight into intestinal
motor function via noninvasive
endoluminal image analysis. Gastro-
enterology 2008; 135: 1155–62.
42 de Iorio F, Malagelada C, Azpiroz F
et al. Intestinal motor activity,
endoluminal motion and transit.
Neurogastroenterol Motil 2009; 21:
1264–e119.
M. Camilleri et al. Neurogastroenterology and Motility
 2010 Blackwell Publishing Ltd882
APPENDIX
Participating study centers
The following is the number of eligible subjects at the investigative sites: Mayo Clinic Rochester (n = 30),
University of Iowa (n = 28), Wake Forest University (n = 28), Jasper Clinic, Inc., Kalamazoo, Michigan (n = 19),
University of North Carolina (n = 18), University of Michigan (n = 15), University of Buffalo VAMC (n = 10), Kansas
University (n = 12), Massachusetts General Hospital (n = 8), Queen Mary University, London, UK (n = 8), Cedars-
Sinai Medical Center Los Angeles (n = 3), and Temple University (n = 1).
Prohibited medications
Two main categories of medication were prohibited prior to or during the studies:
1 Medications which alter gastric pH, including proton pump inhibitors for 7 days prior and including the day of
WMC ingestion; H2 blockers for 3 days including the day of WMC ingestion, and antacids for 1-day prior to
ingestion
2 Medications that affect gastrointestinal motility, including prokinetics, antiemetics, narcotic analgesics,
anticholinergic agents, medications for constipation, 5-HT3 antagonists, antidiarrheal agents, opiates used to treat
diarrhea and NSAIDs
Comparator method
The Metcalf method involves ingestion of a capsule containing 24 radiopaque markers on three successive days
Abdominal X-rays are taken on day 4 (72 h after the ingestion of the first 24 markers) and day 7 (144 h after the
ingestion of the first 24 markers) and the number and distribution of the markers present in the colon are counted.
Colonic transit time is calculated by summing the number of markers visualized on the day 4 and day 7 X-rays and
equating 1 marker to 1 h of colonic transit time. Colonic transit time of >67 h with this ROM method is considered
delayed and is derived from the 95th percentile of colonic transit time of healthy subjects as reported by Metcalf
et al.8 The colonic transit times were reported by the investigators at each study center.
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